From economics to health outcomes: Delving into the significance of reduced insulin prices
The recent substantial price reductions in insulin therapy by major manufacturers prompt an examination of their impact on South Africa (SA)’s healthcare. While Eli Lilly, Novo Nordisk, and Sanofi cut prices on long-acting basal insulin, among others, significantly, these insulins are not on SA...
Saved in:
Main Authors: | M Leuschner, M Strydom, V Steenkamp |
---|---|
Format: | Article |
Language: | English |
Published: |
South African Medical Association
2024-08-01
|
Series: | South African Medical Journal |
Subjects: | |
Online Access: | https://samajournals.co.za/index.php/samj/article/view/2014 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Availability and accessibility of cytotoxic medicines in the WHO model list of essential medicines for childhood cancer in low and lower-middle- income countries: a systematic review
by: Maheeka Seneviwickrama, et al.
Published: (2025-01-01) -
Availability, pricing, and affordability of antithrombotic medicines in Addis Ababa, Ethiopia: implications for health policy
by: Selam Birhanu, et al.
Published: (2025-01-01) -
Budget impact analysis of insulin glargine vs. isophane protamine insulin treatment for patients with type-2 diabetes and severe hypoglycemia in Thailand
by: Unchalee Permsuwan, et al.
Published: (2025-01-01) -
Initiation of insulin therapy in patients with type 2 diabetes: An observational study
by: Zerovnik Spela, et al.
Published: (2022-03-01) -
Euglycemic Diabetic Ketoacidosis in a Pregnant Patient on Insulin Pump Therapy
by: Hesham Yasin, MD, et al.
Published: (2025-01-01)